Even if cDC2s are in many aspects less efficient than cDC1s, such as in taking up tumor antigens, trafficking to draining lymph nodes, producing IL-12, and stimulating CD8+ T cells [25,27,28,32], these cells are very efficient in the presentation of MHC-II-associated tumor antigens to CD4+ T cells [49,50,51,52,53]. This evidence concerns the gene CD4 and neoplasm.